The New Emergency Health Kit 98: Drugs and Medical Supplies for 10,000 People for Approximately 3 Months
(1998; 82 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentAcknowledgments
View the documentIntroduction
Open this folder and view contentsChapter 1: Essential drugs and supplies in emergency situations
Open this folder and view contentsChapter 2: Comments on the selection of drugs, medical supplies and equipment included in the kit
Open this folder and view contentsChapter 3: Composition of the New Emergency Health Kit 98
View the documentAnnex 1: Basic unit: treatment guidelines
Open this folder and view contentsAnnex 2: Assessment and treatment of diarrhoea
Open this folder and view contentsAnnex 3: Management of the child with cough or difficult breathing
View the documentAnnex 4: Sample data collection forms
View the documentAnnex 5: Sample health card
Open this folder and view contentsAnnex 6: Guidelines for suppliers
Open this folder and view contentsAnnex 7: Other kits for emergency situations
Close this folderAnnex 8: Guidelines for Drug Donations48
View the documentSelection of drugs
View the documentQuality assurance and shelf-life
View the documentPresentation, packing and labelling
View the documentInformation and management
Open this folder and view contentsAnnex 9: Model Guidelines for the International Provision of Controlled Medicines for Emergency Medical Care52
Open this folder and view contentsAnnex 10: References
View the documentAnnex 11: Useful addresses
View the documentOrganizations which have collaborated in the preparation of the New Emergency Health Kit 98
View the documentBack Cover
 

Information and management

10. Recipients should be informed of all drug donations that are being considered, prepared or actually underway.

Justification and explanation

Many drug donations arrive unannounced. Detailed advance information on all drug donations is essential to enable the recipient to plan for the receipt of the donation and to coordinate the donation with other sources of supply. The information should at least include: the type and quantities of donated drugs including their International Nonproprietary Name (INN or generic name), strength, dosage form, manufacturer and expiry date; reference to earlier correspondence (for example, the letter of consent by the recipient); the expected date of arrival and port of entry; and the identity and contact address of the donor.

11. In the recipient country the declared value of a drug donation should be based upon the wholesale price of its generic equivalent in the recipient country, or, if such information is not available, on the wholesale world-market price for its generic equivalent.

Justification and explanation

This provision is needed in the recipient country to prevent drug donations being priced according to the retail price of the product in the donor country, which may lead to elevated overhead cost for import tax, port clearance, and handling in the recipient country. It may also result in a corresponding decrease in the public sector drug budget in the recipient country.

Possible exception

In case of patented drugs (for which there is no generic equivalent) the wholesale price of the nearest therapeutic equivalent could be taken as a reference.

12. Costs of international and local transport, warehousing, port clearance and appropriate storage and handling should be paid by the donor agency, unless specifically agreed otherwise with the recipient in advance.

Justification and explanation

This provision prevents the recipient from being forced to spend effort and money on the clearance and transport of unannounced consignments of unwanted items, and also enables the recipient to review the list of donated items at an early stage.

 

to previous section to next section
 

Last updated: April 24, 2012